Xeris Pharmaceuticals Inc (NASDAQ:XERS) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 933,515 shares, a growth of 52.4% from the February 28th total of 612,623 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average trading volume of 466,133 shares, the short-interest ratio is presently 2.0 days.
In related news, insider James E. Flynn sold 7,038 shares of the business’s stock in a transaction dated Tuesday, January 29th. The stock was sold at an average price of $15.12, for a total value of $106,414.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Steven Prestrelski sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $9.56, for a total value of $95,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 620,500 shares of company stock worth $6,178,600 and sold 153,530 shares worth $2,299,553. Insiders own 7.43% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new stake in Xeris Pharmaceuticals in the third quarter worth approximately $262,000. BlackRock Inc. boosted its stake in Xeris Pharmaceuticals by 1,477.7% in the third quarter. BlackRock Inc. now owns 394,416 shares of the company’s stock worth $6,933,000 after buying an additional 369,416 shares in the last quarter. FMR LLC boosted its stake in Xeris Pharmaceuticals by 128.6% in the third quarter. FMR LLC now owns 1,833,031 shares of the company’s stock worth $32,225,000 after buying an additional 1,031,231 shares in the last quarter. Vanguard Group Inc. boosted its stake in Xeris Pharmaceuticals by 920.3% in the third quarter. Vanguard Group Inc. now owns 255,064 shares of the company’s stock worth $4,484,000 after buying an additional 230,064 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in Xeris Pharmaceuticals by 920.3% in the third quarter. Vanguard Group Inc now owns 255,064 shares of the company’s stock worth $4,484,000 after buying an additional 230,064 shares in the last quarter. 40.09% of the stock is owned by institutional investors.
Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.04). The firm had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.10 million. On average, analysts predict that Xeris Pharmaceuticals will post -3.28 earnings per share for the current year.
XERS has been the subject of a number of recent analyst reports. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Zacks Investment Research lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.60.
ILLEGAL ACTIVITY WARNING: This article was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/16/xeris-pharmaceuticals-inc-xers-short-interest-update-3.html.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.